Intra-Cellular Therapies (ITCI) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

ProductGrant
062M125M188M250M312M375M438M500MQ4 2023Q1 2024Q2 2024Q3 2024Q4 2024

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
062M125M188M250M312M375M438M500MQ4 2023Q1 2024Q2 2024Q3 2024Q4 2024

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024

Operating Expenses

Research And Development ExpensesSelling And Marketing ExpensesGeneral And Administrative ExpensesOther Expenses
025M50M75M100M125M150M175M200MQ4 2023Q1 2024Q2 2024Q3 2024Q4 2024

EBITDA

EBITDA
-50M-44M-37M-31M-25M-19M-12M-6M1Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024

EPS

EPSEPS Diluted
000111222Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024

Revenue Variation (%)

Revenue Variation
02581012151820Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
0255075100125150175200Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024

Revenue YoY Variation (%)

Revenue YoY Variation
0918263544526170Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
01122344556687990Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024

Price-to-Earning Ratio

P/E Ratio
-200-175-150-125-100-74-49-241Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024

Income Breakdown

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
04M8M11M15M19M22M26M30MQ4 2023Q1 2024Q2 2024Q3 2024Q4 2024

Per Share Metrics

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
001122233Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024

Expense Ratios

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
000001111Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024
💰 Cash Flow Statement

Operating Cash Flow

Operating Cash FlowCapital ExpenditureFree Cash Flow
0250K500K750K1M1M2M2M2MQ4 2023Q1 2024Q2 2024Q3 2024Q4 2024

Free Cash Flow

Cash At End Of Period
0100M200M300M400M500M600M700M800MQ4 2023Q1 2024Q2 2024Q3 2024Q4 2024

Cash Flow to Debt Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
088M175M262M350M438M525M612M700MQ4 2023Q1 2024Q2 2024Q3 2024Q4 2024
🏦 Balance Sheet
📈 Key Metrics